The Top Line
By Fierce Life Sciences
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Fierce Life Sciences
Category: Business News
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 100
Description
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
| Episode | Date |
|---|---|
|
Big Pharma bounces back in Q2
|
Aug 22, 2025 |
|
The battle of the obesity drug heavyweights
|
Aug 15, 2025 |
|
Is Trump’s MFN pricing order more bark than bite?
|
Aug 08, 2025 |
|
Rebuilding trust: compassionate communication and public health (Sponsored)
|
Aug 04, 2025 |
|
Untangling Sarepta’s gene therapy fallout and a growing trust deficit
|
Aug 01, 2025 |
|
Making sense of China’s R&D ascent
|
Jul 25, 2025 |
|
AI, mentorship and finding your voice in pharma marketing
|
Jul 18, 2025 |
|
Biopharma layoffs aren't letting up
|
Jul 11, 2025 |
|
Peter Pitts talks FDA direction, industry communication (Sponsored)
|
Jul 08, 2025 |
|
Teva’s CEO shares ‘Pivot to Growth’ progress
|
Jun 27, 2025 |
|
AbbVie, ADCs and the future of cancer care
|
Jun 20, 2025 |
|
Inside Fierce Medtech's Fierce 15
|
Jun 13, 2025 |
|
Inside ASCO 2025: Big data drops and a towering campaign
|
Jun 06, 2025 |
|
Forging the future of cell therapy: Bayer and BlueRock’s unique journey (Sponsored)
|
Jun 02, 2025 |
|
Science-led storytelling takes center stage in pharma communications (Sponsored)
|
Jun 02, 2025 |
|
Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview
|
May 30, 2025 |
|
A Fierce breakdown of the 'most favored nation' executive order
|
May 16, 2025 |
|
Angela Hwang on her pivot from Big Pharma to biotech
|
May 09, 2025 |
|
ElevAAte and the push for East Asian American leaders in biopharma
|
May 02, 2025 |
|
Angus on Angus: A Fierce oncology discussion
|
Apr 25, 2025 |
|
Navigating Trump’s tariffs for pharma
|
Apr 18, 2025 |
|
Q1 biopharma layoff trends, plus expectations for Q2
|
Apr 11, 2025 |
|
A closer look at pharma's top R&D budgets
|
Apr 04, 2025 |
|
What diversity means in medtech
|
Mar 28, 2025 |
|
5 Key Questions About Precision Patient Marketing—Answered (Sponsored)
|
Mar 24, 2025 |
|
A closer look at pharma’s top patent losses in 2025
|
Mar 21, 2025 |
|
Agenus CMO touts immunotherapy advances on The Top Line
|
Mar 17, 2025 |
|
Breaking down pharma’s fourth-quarter sales boom
|
Mar 14, 2025 |
|
Inside the Future of Aseptic Manufacturing with GRAM (Sponsored)
|
Mar 10, 2025 |
|
Bridging the gap from clinical trials to real-life HIV care (Sponsored)
|
Mar 10, 2025 |
|
A look at biotech's biggest money raisers of 2024
|
Mar 07, 2025 |
|
Research reveals ‘ticking DNA clock’ behind Huntington’s disease
|
Feb 28, 2025 |
|
What were the biggest clinical trial flops of 2024?
|
Feb 21, 2025 |
|
A heartwarming roundup of cardiovascular news and most-loved stories
|
Feb 14, 2025 |
|
Looking ahead at the most anticipated drug launches of 2025
|
Feb 07, 2025 |
|
What to expect from the biotech IPO market in 2025
|
Jan 31, 2025 |
|
Recapping the 2025 J.P. Morgan Healthcare Conference
|
Jan 24, 2025 |
|
Fierce's forecasts for the next year in biopharma
|
Jan 17, 2025 |
|
An additional treatment option with TAGRISSO® (osimertinib) (Sponsored)
|
Jan 10, 2025 |
|
Breaking down the 55 new drug approvals of 2024
|
Jan 10, 2025 |
|
Fierce 50 honorees look ahead: AI, rural health, antibiotic resistance, maternal care and more
|
Dec 20, 2024 |
|
Novo Nordisk’s chief scientific officer looks to the future of GLP-1s
|
Dec 13, 2024 |
|
What can we learn from 2024’s biotech IPOs?
|
Dec 06, 2024 |
|
Meet 2024’s fiercest women in life sciences
|
Nov 22, 2024 |
|
Misconduct and the future of neurodegenerative disease research
|
Nov 15, 2024 |
|
Dig into this year’s Fierce Biotech Graveyard, layoff numbers
|
Nov 08, 2024 |
|
Drug pricing and the 2024 presidential election
|
Nov 01, 2024 |
|
Discover Turbine’s way to build avatars true to patient biology [Sponsored]
|
Oct 28, 2024 |
|
The pulse of the medtech industry
|
Oct 25, 2024 |
|
Where are they now? Catching up with past Fierce 15 honorees
|
Oct 18, 2024 |
|
Revolutionizing gene therapy logistics with Cryoport's Elite solution [Sponsored]
|
Oct 14, 2024 |
|
A revival in neuro therapeutics
|
Oct 11, 2024 |
|
Breaking down BIOSECURE—Industry implications and what comes next
|
Oct 04, 2024 |
|
ESMO, WCLC lung cancer data spark hope—and debate
|
Sep 27, 2024 |
|
Recapping Digital Pharma East 2024
|
Sep 20, 2024 |
|
A closer look at the Fierce 50
|
Sep 13, 2024 |
|
A look at flu vaccine manufacturing and supply in the post-pandemic era
|
Sep 06, 2024 |
|
Driving flu vaccine uptake in the post-pandemic era
|
Aug 29, 2024 |
|
The Crucial Role of HEK293 DNA Quantification in Biotherapeutics [Sponsored by Bio-Rad Laboratories]
|
Aug 26, 2024 |
|
What Chevron’s overturn means for biopharma
|
Aug 23, 2024 |
|
The TROP2 race for supremacy
|
Aug 16, 2024 |
|
A closer look at Fierce Biotech's Fierce 15
|
Aug 09, 2024 |
|
What 'The Next Berlin Patient' and a PrEP’s 100% efficacy mean for HIV drug development
|
Aug 02, 2024 |
|
Fierce 15: Where are they now?
|
Jul 26, 2024 |
|
Former FTC director weighs in on Novo's $16.5B deal with Catalent
|
Jul 19, 2024 |
|
Find out what to expect from the PDA/FDA Joint Regulatory Conference (Sponsored by Parenteral Drug Association)
|
Jul 15, 2024 |
|
A look at Big Pharma’s top-paid CEOs
|
Jul 12, 2024 |
|
The best biopharma M&A deals
|
Jun 28, 2024 |
|
A closer look at 'friend-shoring' and the drug shortage challenge
|
Jun 21, 2024 |
|
Inside this year’s ASCO: Biggest data drops, trends and the best exhibit booth
|
Jun 14, 2024 |
|
A look at the top 10 pharma drug ad spenders
|
Jun 07, 2024 |
|
A cell therapy reckoning
|
May 31, 2024 |
|
Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III)
|
May 24, 2024 |
|
[Sponsored] Opportunities & Challenges of Digital Pathology Adoption in CDx Development
|
May 22, 2024 |
|
[Sponsored] Unlocking health equity: The promise of digital health technologies
|
May 20, 2024 |
|
Advancements in cell & gene therapy manufacturing (Part II)
|
May 17, 2024 |
|
Fulfilling the promise of cell & gene therapies through manufacturing (Part I)
|
May 10, 2024 |
|
A closer look at 2023's top biopharma deals and what lies ahead
|
May 03, 2024 |
|
A look at pharma revenue rankings
|
Apr 26, 2024 |
|
Winning formulas for the best biotech and drug names
|
Apr 19, 2024 |
|
[Sponsored] What does the future of specialist distribution look like?
|
Apr 15, 2024 |
|
Deep dive: Biopharma layoffs in Q1
|
Apr 12, 2024 |
|
The unrecognized threat of PAD
|
Apr 05, 2024 |
|
The top money raisers in biotech
|
Mar 29, 2024 |
|
A closer look at European biotech investment in 2024
|
Mar 22, 2024 |
|
Inclusivity in psoriasis trials with Takeda
|
Mar 15, 2024 |
|
Fierce Medtech's Fierce 15
|
Mar 08, 2024 |
|
[Sponsored] A Person-Centered Approach to Achieving Long-Term Success
|
Mar 04, 2024 |
|
CAR-T boxed warnings: What comes next?
|
Mar 01, 2024 |
|
Breaking down Eli Lilly’s ESG formula
|
Feb 23, 2024 |
|
Gene editing's next act
|
Feb 16, 2024 |
|
The most anticipated drug launches of 2024
|
Feb 09, 2024 |
|
[Sponsored] Turning information into outcomes with MedThink Communications
|
Feb 05, 2024 |
|
[Sponsored] Talking technology and collaboration with Cytiva
|
Feb 05, 2024 |
|
Navigating the future of medical AI
|
Feb 02, 2024 |
|
Closing the $1 trillion women’s health gap
|
Jan 26, 2024 |
|
A closer look at the bounty of new drug approvals in 2023
|
Jan 19, 2024 |
|
The year in biotech
|
Dec 22, 2023 |
|
[Sponsored] Addressing the evolving needs of pharma for CDx development
|
Dec 20, 2023 |
|
A closer look at the Fierce 50
|
Dec 15, 2023 |